+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Clinical Trial Report COVID-19 Special Edition

  • ID: 5025163
  • Report
  • April 2020
  • Region: Global
  • 8 Pages
  • i3 Consult
1 of 4

FEATURED COMPANIES

  • Algernon
  • Chimerix
  • Genomics
  • Inovio
  • Moderna
  • Pfizer
  • MORE

The cataclysm caused by the COVID-19 pandemic has impacted on clinical trials in terms of alternatives for study participants, enhanced operational and financial support for progressively more complex trial protocol designs, and greater collaboration among sponsors. Therefore, presented here is a timely summarised report of new candidate antiviral and vaccine therapies undergoing clinical trials worldwide in the pursuit of gaining regulatory approval for treatment and/or prophylaxis against SARS-CoV-2 coronavirus infection.

Countries Covered:

  • China
  • EU
  • South Korea
  • US

Products Mentioned:

  • INO-4800 Vaccine
  • BNT162 Vaccine
  • NP-120 (Ifenprodil)
  • Vafidemstat
  • IPH5401 (Avdoralimab)
  • mRNA-1273 Vaccine
  • Dociparstat Sodium (DSTAT)
  • Ryoncil (Remestemcel-L)
  • Pacritinib
  • NT-300 (Nitazoxanide extended-release tablets)

 

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Algernon
  • Chimerix
  • Genomics
  • Inovio
  • Moderna
  • Pfizer
  • MORE
  • Introduction
  • Table of Findings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Algernon
  • BioNTech
  • CTI BioPharma
  • Chimerix
  • Genomics
  • Innate
  • Inovio
  • Mesoblast
  • Moderna
  • ORYZON
  • Pfizer
  • Pharma
  • Pharmaceuticals
  • Romark Labs
Note: Product cover images may vary from those shown
Adroll
adroll